ABSTRACT
Ischemic stroke has the characteristics of high morbidity and high mortality, which seriously endanger human health.According to the statistics, ischemic stroke in China accounts for about 80% of stroke cases, and its mortality rate is as high as 50%, but most of the ischemic stroke patients who survive have sequelae, such as hemiplegia, aphasia and so on.In recent years, people have continuously studied the pathological cascade of ischemic stroke, and also achieved some good results in animal model experiments, however, the clinical results are not satisfactory. Nowadays, the better clinically effective therapeutic drug is tissue plasminogen activator, but due to the limited time window,only a small number of patients can apply this drug in time to achieve the effect.Therefore,it is essential to study drugs that are definitive and can benefit a large number of patients with ischemic stroke.The development of traditional medicines is not as fast as the development of new drugs. For ischemic stroke,we can also turn from the study of the pathogenesis of ischemic stroke to the study of traditional drugs for the endogenous neuroprotection of ischemic stroke, and look for effective targets for neuroprotection based on traditional medicine.The multi-targets and multi-effects for the acute and convalescent phases of ischemic stroke is a direction explored by researchers, which also provides some evidence for more effective drugs for the treatment of ischemic stroke.